Advances in understanding prognosis in myeloma. Smith D et al. Br J Haematol. 2016 Sep 8. doi: 10.1111/bjh.14304. [Epub ahead of print]. Stem Cell Transplantation In Multiple Myeloma. Offidani M et al. Curr Cancer Drug Targets. 2016 Sep 19. [Epub ahead of print]. The role of high-dose melphalan and autologous stem cell transplant in the rapidly evolving era of modernmultiple myeloma therapy. Voorhees PM et…
Therapeutic drug monitoring enables safe and effective lenalidomide therapy in patients with multiple myeloma on hemodialysis. Kobayashi T et al. Ann Hematol. 2016 Sep 6. [Epub ahead of print]. Mid-term outcomes after radiofrequency-targeted vertebral augmentation in the treatment of myeloma associated vertebral fractures. Ali T et al. Technol Health Care. 2016 Sep 14;24(5):745-51. doi: 10.3233/THC-161222. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile…
Pathological Fracture In Odontoid Process In Multiple Myeloma. Demirci U et al. Turk J Haematol. 2016 Sep 23. doi: 10.4274/tjh.2016.0020. [Epub ahead of print]. Pinpointing a Factor in Myeloma Bone Disease. [No authors listed]. Cancer Discov. 2016 Sep 22. [Epub ahead of print]. Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma. Wanchoo R et al. Clin J Am Soc Nephrol. 2016 Sep 21. pii:…
Upfront autologous stem cell transplantation for newly diagnosed elderly multiple myeloma patients: a prospective multicenter study. Garderet L et al. Haematologica. 2016 Sep 9. pii: haematol.2016.150334. [Epub ahead of print]. Outcome with lenalidomide plus dexamethasone followed by early autologous stem cell transplantation in patients with newly diagnosed multiple myeloma on the ECOG-ACRIN E4A03 randomized clinical trial: long-term follow-up. Biran N et al. Blood Cancer…
Pain is one of the most common and debilitating symptoms of progressive myeloma. This guidance written by NICE outlines safe use of opioids for adults with advanced disease.
IFM (Intergroupe francophone du myélome) recommendations for uniform interpretation of serum and urine protein electrophoresis in multiple myeloma diagnosis and follow-up. Dejoie T et al. Ann Biol Clin (Paris). 2016 Aug 1;74(4):429-441. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma. Li Y et al. Oncotarget. 2016 Aug 19. doi: 10.18632/oncotarget.11418. [Epub ahead of print]. The independent…
Gastric Outlet Obstruction due to Gastrointestinal Amyloidosis. Cohen JA et al. J Gastrointest Surg. 2016 Aug 19. [Epub ahead of print]. Paraprotein-Related Kidney Disease: Diagnosing and Treating Monoclonal Gammopathy of Renal Significance. Rosner MH et al. Clin J Am Soc Nephrol. 2016 Aug 15. pii: CJN.02920316. [Epub ahead of print]. Primary pulmonary plasmacytoma: a case report introduction. Nie S et al. World J…
New investigational drugs with single-agent activity in multiple myeloma.
Rajan AM et al. Blood Cancer J. 2016 Jul 29;6(7):e451. doi: 10.1038/bcj.2016.53.
Genomic complexity of multiple myeloma and its clinical implications. Manier S et al. Nat Rev Clin Oncol. 2016 Aug 17. doi: 10.1038/nrclinonc.2016.122. [Epub ahead of print]. Baseline characteristics, chromosomal alterations and treatment affecting prognosis of deletion 17p in newly diagnosed myeloma. Merz M et al. Am J Hematol. 2016 Aug 10. doi: 10.1002/ajh.24533. [Epub ahead of print]. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple…
Is Maintenance Therapy for Everyone? Nooka AK et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S139-44. doi: 10.1016/j.clml.2016.02.011. How to Think About Risk in Myeloma. Krishnan A. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S135-8. doi: 10.1016/j.clml.2016.02.015. Clonal Evolution in Multiple Myeloma. Fakhri B et al. Clin Lymphoma Myeloma Leuk. 2016 Aug;16 Suppl:S130-4. doi: 10.1016/j.clml.2016.02.025. Concise review: Treatment of multiple myeloma in the very elderly: How do novel agents fit in? Kint N et al. J…